Dеbra VANDERWERF, individually and as next friend for Riley Vanderwerf and Tanner Vanderwerf, minors; Estate of William K. Vanderwerf, Plaintiffs-Appellants, v. SMITHKLINE BEECHAM CORPORATION, d/b/a Glaxosmithkline, Defendant-Appellee.
No. 08-3218.
United States Court of Appeals, Tenth Circuit.
April 27, 2010.
603 F.3d 842
Andrew Bayman (with Chilton Davis Varner, Stephen B. Devereaux, Todd P. Davis, and Jennifer C. Kane, King &
Before HENRY, Chief Judge, BRISCOE and LUCERO, Circuit Judges.
HENRY, Chief Judge.
The plaintiffs, the Vanderwerf family and the estate of William K. Vanderwerf, appeal the district court‘s grant of summary judgment to SmithKline Beecham Corporation (“SKB“), the pharmaceutical company who manufactured paroxetine, under the label Paxil, a medication prescribed to the decedent, who later committed suicide. We are unable, however, to overlook the ill-timed filing of the Vanderwerfs’ notice of appeal, because without a timely notice оf appeal, we are deprived of jurisdiction to review the merits of the action. As a result of the plaintiffs’ sua sponte withdrawal of their motion for reconsideration, their appeal is from an order entered seven months earlier. We must grant SKB‘s motion to dismiss this appeal as untimely filed.
I. BACKGROUND
The Vanderwerfs suffered a tragic loss when their family‘s father, William, who suffered from clinical depression, committed suicide in 2003. The family brought suit seeking damages from SKB, thе manufacturer of Paxil, which Mr. Vanderwerf had been prescribed to reduce his depression and anxiety. In various claims asserting strict liability, negligence and breach of implied warranty, the complaint alleged that SKB failed to warn or instruct about the risks of Paxil. The Vanderwerfs further alleged that SKB did not adequately warn Mr. Vanderwerf‘s treating physicians that Paxil increases the risk of suicidal behavior and/or suicide precursors across all psychiatriс disorders for adults of all ages. Under this theory, had the treating physicians received such warnings, they would have (1) not prescribed Paxil; (2) monitored Mr. Vanderwerf more closely; and/or (3) warned Mr. Vanderwerf and his family of the increased risk. The Vanderwerfs claimed that had any of these three events taken place, Mr. Vanderwerf would not have committed suicide.
SKB moved for summary judgment, arguing that (1) the court should exclude the testimony of the Vanderwerfs’ proffered witness, Dr. Peter Breggin; (2) without an expert‘s testimony the Vanderwerfs cannot methodologically prove general or specific causation; and (3) the Vanderwerfs could not demonstrate proximate causation because, had SKB provided additional warnings to the treating physicians, the doctors would not have changed their course of treatment.
On January 9, 2008, the district court, in a thirty-one page order, granted summary judgment to SKB. The court first notеd that because suicidality occurs in many people who are not exposed to Paxil or any other medicine, the plaintiffs needed to present expert testimony to meet their burden of proving medical causation that Paxil can cause suicide (general causation) and that Paxil more likely than not caused Mr. Vanderwerf‘s suicide (specific causation). The court excluded Dr. Breggin‘s testimony “[f]or substantially the reasons statеd in [SKB‘s motion to exclude Dr. Breggin‘s testimony and its reply brief in support of that motion].”1 Aplts’ App. vol.
As to general causation, the district court also found that (1) Dr. Breggin did not put forth an accepted methodology for determining general causation (i.e., that Paxil can cause suicide); (2) failed to account for the substantial body of evidence indicating no causal link between Paxil and suicide or suicidal behavior in adults, particularly those beyond the age of thirty; аnd (3) did not sufficiently distinguish statistical “association” from causation. Id.
The court similarly concluded that because Dr. Breggin could not testify, the Vanderwerfs could not establish that Paxil more likely than not caused Mr. Vanderwerf‘s suicide (i.e., specific causation). Id. at 2358. The court stated that even given SKB expert Dr. John Kraus‘s testimony, any conclusion that Paxil more likely than not caused Mr. Vanderwerf‘s suicide “would be sheer speculation.” Id. Because the Vanderwеrfs offered no evidence of specific causation aside from the testimony of Dr. Breggin, the court sustained SKB‘s motion for summary judgment on this alternative ground.
Finally, the district court determined that even had the Vanderwerfs established general and specific causation, they could not establish proximate causation. Under Kansas‘s learned intermediary doctrine,2 the court first assumed that SKB should have provided labeling and warnings that (1) Paxil increased the risk of suicidal behavior and (2) Paxil increased the risk of suicide precursors such as activation, overstimulation, anxiety, insomnia and agitation. Additionally, the court assumed that Paxil could have provided a warning consisting of information that SKB disclosed in 2006 in the DHCP letter that there existed a “possible increase in risk of suicidal behavior” in adults who took Paxil. Aplts’ App. at 2345.
The court acknowledged the Vanderwerfs’ argument that if there had been a warning that Paxil increased the risk of suicide in adults, Dr. John Crane, Mr. Vanderwerf‘s treating physician at the time of the suicide, would have passed along the additional warning and “watched [Mr. Vanderwerf] considerably closer.” Id. at 2364. Dr. Crane testified that he might “not even have used [Paxil] in a certain individual,” had he known of the risks involved. Id. But given the positive results
In granting summary judgment to SKB, the district court concluded that “[s]peculation about how this tragedy might have been avoided is absolutely understandable and perhaps inevitable, but [the Vanderwerfs] cannot escape summary judgment based on speculation.” Id. at 2367.
On January 17, 2008, еight days after the district court granted summary judgment to SKB, the Vanderwerfs filed a
II. DISCUSSION
The Vanderwerfs argue that their withdrawal of their
The Vanderwerfs withdrawal of their Rule 59(e) motion and filing of a notice of appeal do not satisfy the Federal Rules of Appellate Procedure ‘s requirements
As
The Vanderwerfs failed to comply with the jurisdictional requirements of
Here, the Vanderwerfs’ withdrawal of the
The Vanderwerfs’ notice of appeal designated the January 9, 2008 judgment granting summary judgment to SKB as the judgment being appealed: “[the Vanderwerfs] appeal from the final judgment of the District Court for the District of Kansas, entered in this case on January 9, 2008.” Notice of Aрpeal filed Aug. 8, 2008. The notice of appeal acknowledges that the Vanderwerfs “timely filed a Motion to Alter or Amend Judgment with Memorandum in Support and then withdrew this Motion on August 8, 2008, before the District Court ruled on it.” Id. The Vanderwerfs argue that the filing, and subsequent withdrawal, of a
The Vanderwerfs point to several circuit cases for support, but their arguments аre unpersuasive. At oral argument, when asked for its strongest Tenth Circuit case, counsel for the Vanderwerfs pointed to OXY USA, Inc. v. Babbitt, 230 F.3d 1178, 1183 n. 5 (10th Cir.2000), vacated on other grounds, 268 F.3d 1001 (10th Cir.2001) (en banc). In OXY, after the district court
The remaining cases relied upon by the Vanderwerfs similarly fail to convince us that the timing of their notice of appeal bestows jursidiction on this court. The cases primarily focus on when the thirty-day clock should be reset for purposes of determining the timeliness of a party‘s notice of appeal, and indicate that the proper indicator is the date of the filing of the order аcknowledging the withdrawal of or denying the
The Vanderwerfs’ strongest case appears to be United States v. Rodriguez, 892 F.2d 233, 234 (2d Cir.1989), where the government filed a
The Vanderwerfs also point to the Sixth Circuit‘s brief unpublished disposition involving a variety of parties and claims in Chrysler Motors Corp. v. Country Chrysler, Inc., No. 89-1472, 1989 WL 100084, at *1 (6th Cir. July 31, 1989),5 where the party seeking to appeal after the withdrawal of a
Although we notе that there is no suggestion that the Vanderwerfs acted in bad faith, we are hamstrung by the mandatory procedural rules. The Vanderwerfs had other options, which may have allowed this court to take jurisdiction. First, the Vanderwerfs could have filed a motion requesting a ruling. Second, they could have continued to wait for a ruling, or sought a writ of mandamus in this court, which, if granted would compel the district court to rule on the
III. CONCLUSION
We recognize the severity of today‘s holding, and empathize with the plight of parties who are effectively prohibited from filing a notice of appeal because of the inaction of a district court. But we must rely upon the unambiguous standard we have consistеntly applied to the timeliness requirements of
LUCERO, Circuit Judge, dissenting.
My colleagues in the majority conclude that we lack jurisdiction because the notice of appeal was untimely. Yet the plain language of
As the majority notes, under the
Summary judgment was entered for SmithKline Beecham (“SKB“) on January 9, 2008. The Vanderwerfs filed a motion to alter or amend the judgment on January 17, 2008, well within the filing deadline under
According to the majority, the filing of a
Under the language of
My reasoning is in accord with pertinent authorities. My colleagues have not cited to any cases holding that a party‘s withdrawal of a
SKB makes two equitable arguments in favor of its proposal that the
For the foregoing reasons, I dissent. I would entertain the present appeal, or remand this case to allow the district court an opportunity to rule on the Vanderwerf‘s
Notes
Id. (quoting Humes v. Clinton, 246 Kan. 590, 792 P.2d 1032, 1039 (1990) (quoting Terhune v. A.H. Robins Co., 90 Wash.2d 9, 577 P.2d 975, 978 (1978))). The record of the district court states that this case is closed, but no order closing the case has been entered by the assigned judge.Where a product is available only through the services of a physician, the physician acts as a learned intermediary between the manufacturer or seller and the patient. It is his duty to inform himself of the qualities and characteristics of those products which he prescribes for or administers to or uses on his patients, and to exercise an independent judgment, taking into account his knowledge of the pаtient as well as the product. The patient is expected to and, it can be presumed, does place primary reliance upon that judgment. . . . Thus, if the product is properly labeled and carries the necessary instructions and warnings to fully apprise the physician of the proper procedures for use and the dangers involved, the manufacturer may reasonably assume that the physician will exercise the informed judgment thereby gained in conjunction with his own independent learning, in the best interest of the patient. It has also been suggested that the rule is made necessary by the fact that it is ordinarily difficult for the manufacturer to communicate directly with the consumer.
